|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
UNDER CONSTRUCTION | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Tuesday, October 24, 2006
BioMS Medical expands pivotal multiple sclerosis trial into the Baltic StatesBioMS Medical Corp (TSX: MS - News), a leading developer in the treatment of multiple sclerosis (MS), today announced it has received approval in all of the Baltic States (Lithuania, Estonia, and Latvia) from their respective agencies to begin enrolling patients into its ongoing pivotal phase II/III trial of MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive multiple sclerosis (SPMS).
|